5 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis CNM-Au8, Placebo - Relapsing Remitting Multiple Sclerosis, Optic Neuropathy | Phase 2 | Terminated | Clene Nanomedicine | 73 | 2018-11-23 | 2023-04-03 |
| Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 255 | 2013-10-01 | 2016-05-11 |
| A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Pleneva TM BGC20-0134, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Boston Scientific Corporation | 173 | 2009-11-01 | 2022-06-03 |
| Flupirtine as Oral Treatment in Multiple Sclerosis Flupirtine, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Charite University, Berlin, Germany | 30 | 2007-12-01 | 2018-03-20 |
| An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease Laquinimod, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Teva Pharmaceutical Industries, Ltd. | 257 | 2005-12-07 | 2019-03-27 |
Multiple Sclerosis, Relapsing-Remitting (5) · Demyelinating Diseases (2) · Camurati-Engelmann Syndrome (1) · Multiple Sclerosis (1) · Neuritis (1) · Optic Nerve Diseases (1)
Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5) · Immune System Diseases (5) · Nervous System Diseases (5) · Multiple Sclerosis (4) · Demyelinating Diseases (3) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cranial Nerve Diseases (1) · Eye Diseases (1) · Genetic Diseases, Inborn (1) · Musculoskeletal Diseases (1) · Neuromuscular Diseases (1)
Glatiramer Acetate (1) · flupirtine (1) · laquinimod (1)
Boston Scientific Corporation (1) · Charite University, Berlin, Germany (1) · Clene Nanomedicine (1) · EMD Serono (1) · Teva Pharmaceutical Industries, Ltd. (1)
Germany (3) · Poland (3) · Russia (3) · Spain (3) · Czechia (2) · Hungary (2) · Italy (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Finland (1)
Friedemann Paul, MD (1) · Giancarlo Comi (1) · Heidi Beadnall, MD (1)
2005 (1)